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Abstract  
Background 
Semantic Web Technology (SWT) makes it possible to integrate and search the large 
volume of life science datasets in the public domain, as demonstrated by well-known 
linked data projects such as LODD, Bio2RDF, and Chem2Bio2RDF. Integration of 
these sets creates large networks of information. We have previously described a tool 
called WENDI for aggregating information pertaining to new chemical compounds, 
effectively creating evidence paths relating the compounds to genes, diseases and so 
on. In this paper we examine the utility of automatically inferring new compound-
disease associations (and thus new links in the network) based on semantically 
marked-up versions of these evidence paths, rule-sets and inference engines. 
Results 
Through the implementation of a semantic inference algorithm, rule set, Semantic 
Web methods (RDF, OWL and SPARQL) and new interfaces, we have created a new 
tool called Chemogenomic Explorer that uses networks of ontologically annotated 
RDF statements along with deductive reasoning tools to infer new associations 
between the query structure and genes and diseases from WENDI results. The tool 
then permits interactive clustering and filtering of these evidence paths.  
Conclusions 
We present a new aggregate approach to inferring links between chemical compounds 
and diseases using semantic inference. This approach allows multiple evidence paths 
between compounds and diseases to be identified using a rule-set and semantically 
annotated data, and for these evidence paths to be clustered to show overall evidence 
linking the compound to a disease. We believe this is a powerful approach, because it 
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allows compound-disease relationships to be ranked by the amount of evidence 
supporting them. 
Background  
Recent advances in chemical & biological sciences have led to an incredible increase 
in the volume of information about known chemical compounds, genes, diseases, and 
assays. Statistical data from the PubChem Substance Database of chemical structures, 
shows an increase from 35,379,748 structures in 2007 to 69,088,100 in 2010; the 
number of PubChem Bioassays increased from around 1000 in 2008 to 434,635 in 
2010[1], and there are 726,872 compound records and 2,925,588 activities in the 
chemogenomic ChEMBL[2] dataset. Numerous other chemical, chemogenomic, and 
biological data (including data extracted from the scholarly literature) are also 
available including ChEBI[3], CTD[4], KEGG[5] and Medline[6] inter alia. Many 
well-known search engines for these data resources have been developed like 
PubChem, which provides chemical structure search and bioassay search. This search 
engine returns an abundant supply of chemical information and bioactive information 
based on PubChem Bioassay data. ChemSpider[7] links together compound 
information across the Web and provides free text and structure search access to 
millions of chemical structures. It offers multiple search modes to do chemical 
information searching on the basis of hundreds of data vendors.  
We can imagine all these information resources as buckets for pieces of a very large 
jigsaw puzzle, each bucket containing only pieces of a certain color. To assemble the 
full picture we need to be able to search and apply algorithms that span across 
different buckets seamlessly. There are many technologies of utility for this, most 
recently from the Semantic Web Technology (SWT) community, like XML (for 
describing data), OWL (for describing ontologies and taxonomies), and RDF (for 
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describing relationships) are allowing data aggregation and the representation of 
meaning and relationships in the data, and are now being quite widely applied for life 
science data. LODD[8], Bio2RDF[9], Chem2Bio2RDF[10] demonstrate not only how 
SWT can enable integration of multiple sources, but also complex query processing 
using the SPARQL language. Our resource, Chem2Bio2RDF, integrates six 
categories of data based on the kinds of biological and chemical concepts and 
relationships they represent: chemical & drug, protein & gene, chemogenomics, 
systems (i.e., PPI and pathway), phenotype (i.e., disease and side effect) and 
literature. However, the current version of Chem2Bio2RDF lacks a formal ontology 
so it is hard for users to read and understand the meaning of the metadata and harder 
to do further inference. Once an integrated network of compounds, genes, diseases, 
etc. is in place (with an appropriate ontology), as PharmGKB[11] establishes 
knowledge about the relationships among drugs, diseases and genes, including their 
variations and gene products, it becomes possible to semantically infer new links in 
the network (i.e. identify new associations) via sets of rules, and inference engines 
that use these rules. For example, we might have a rule that if a chemical compound A 
is highly similar to a drug D that is known to be active against a protein target T, we 
infer an association (and thus a network link) between A and T (possibly annotated 
with a confidence value).  Semantic inference has been used in various applications 
including knowledge-based recommender systems[12] and human-machine 
communication[13], but there have few applications in the life sciences, 
Neurocommons[14] uses SWT for assembling and querying biomedical knowledge 
from multiple sources and disciplines. With this system, scientists will be able to load 
in lists of genes that come off the lab robots, and get back those lists of genes with 
relevant information around them based on the public knowledge[15]. SciNetS 
 - 5 - 
Search[16] is an inference search over integrated life science databases using SWT. It 
can implement cross-domain search and use statistical scoring. All the metadata of 
databases are described as a set of triples consisting of two bio-items and relationships 
between these items. GoRouter[17] is building an RDF model to do semantic query 
and inference, but the inference is restricted to the Gene Ontology and its related 
associations. 
In our previous paper [18], we introduced a novel tool, WENDI (Web Engine for 
Non-Obvious Drug Information), for aggregating information related to a compound 
to identify relationships. WENDI probes the potential biological properties of the 
compound using predictive models, databases, and the scholarly literature, in 
particular, to find non-obvious relationships between the compound and assays, 
genes, and diseases, which cross over different types of data sources. The purpose of 
WENDI is not just to return data about a compound (such as in a database search): 
rather it allows a researcher to understand the context in which a compound operates, 
and to find clues which help them understand properties of the compound that they 
might not otherwise have discovered. WENDI does data integration for particular 
query compounds and represents its result graph in XML.  WENDI architecture is 
shown in Figure 1. 
Figure 1. WENDI Architecture (WENDI main web interface is show at the upper 
right corner) 
 
WENDI has good performance on data integration, but it relies on the user manually 
find associations among the kinds of results presented. At this point, we thus extended 
WENDI work to use semantic inference and rules to automatically infer new 
associations based on the WENDI XML results. These new associations in aggregate 
form clusters of association that build evidence of an association between compounds 
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and diseases via multiple sources or evidence paths.  We have implemented this in a 
tool called Chemogenomic Explorer that uses networks of ontologically-enabled RDF 
statements (e.g. the query compound C is similar to compound D, drug D is active in 
assay A, assay A is associated with gene G) along with deductive reasoning tools to 
infer relationships between the query compound and genes and diseases, this will 
allow us to cluster insights by disease, and then prioritize the output based on the 
amount of evidence linking a compound to a disease. 
Methods 
The WENDI web service is used to create an initial set of relational paths in XML. 
CE adds to the previously reported capabilities of WENDI through (i) the application 
and inference engine and rule set to enable new associations to be inferred; (ii) 
clustering and filtering of inferred evidence paths in a completely new interface and 
(iii) the application of Semantic Web languages and methods (RDF, SPARQL, OWL) 
to enable a much broader range of capabilities including creation and mining of 
evidence paths, and the annotation of relationships using the ontology. These new 
methods are described below. 
WENDI XML includes the direct relationships between similar compounds and 
bioassays, similar compounds and literature references, bioassays and genes/diseases, 
and so on. The process of importing this information into CE is as follows: 1. Data 
preparation as described in section 2.1; 2. Semantic representation using a CE 
ontology and presentation in RDF format, described in section 2.2; 3. Rule-based 
Inference described in 2.3; and 4. Path ranking based on the number of properties for 
each disease described in 2.4. 
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Data preparation  
WENDI aggregates information from diverse data sources and predictive models 
including PubChem Compound, PubChem Bioassay, PubChem3D [19], 
DrugBank[20], MRTD[21], CTD[4], ChEMBL[3], HuGEpedia[22], KEGG[5], and 
Medline[6]. Because not all of these sources have gene/disease terms related, we first 
extract the data with gene/disease information, such as PubChem Bioassay, CTD, 
ChEMBL, HuGEpedia and Medline. We employed different approaches according to 
the different datasets: for CTD, which already has compound-disease relation 
information, we extract such relationships directly; but for other data, the links 
between compounds and diseases are indirect. There are two ways to mine this 
information in the data preparation section. PubChem bioassay as an example, (i) 
implementing a SQL function “position” to find gene or disease terms from 
Phenopred Matrix[23] occurring in the description of the bioassay, then again based 
on the Phenopred Matrix to find associations between gene and disease, finally the 
link between bioassay-gene-disease can be established; (ii) using the GO 
ontology[24], we performed the same SQL clause to find which GO terms are noted 
in the description of bioassay, identified the genes associated with the GO term on the 
basis of GO annotation, then used the Phenopred matrix to find which diseases are 
linked to these genes. More information about this extraction can be found in our 
WENDI paper [18]. 
We extracted the above information from WENDI XML using XML DOM [25]. All 
the information is extracted into 4 groups: Active-Bioassay, CTD, Chembl, and 
Literature, which include compound, gene, disease, or bioassay and journal 
information. 
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Data representation 
In order to provide a formal description of concepts, terms, and relationships within 
the WENDI knowledge domain and to make semantic inference possible, we use the 
Web Ontology Language (OWL) to build the CE ontology and the Resource 
Description Framework (RDF) in a variety of data interchange formats (e.g. 
RDF/XML, N3, Turtle, N-Triples) to present CE data based on the CE ontology.  
CE OWL ontology is constrained for using in our system: i.e., it is an ontology 
specific to the datasets used in CE and is not a generalized chemogenomic ontology. 
Within the ontology we use the following entity classes: Chemical Compound, 
BioAssay, Journal Article, Gene, and Disease. These entities can be associated by 
relational ontological terms as shown in Table 1. Also the entity and relational terms 
can then be combined to express entity-relationship-entity triples, which are suitable 
for representation in RDF. Some triple examples are given in Table 2.  
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Table 1. Examples of Object Properties and Classes for the CE Ontology 
Properties Classes Explanation 
isSimilarTo 
Chemical Compound,  
Chemical Compound 
Chemical Compound is similar to 
Chemical Compound 
isActiveIn 
Chemical Compound,  
PubChem BioAssay 
Chemical is tested active in the 
bioassay 
isContainedIn 
Chemical Compound,  
Journal Article 
Chemical is contained in the article 
hasGenes 
Pubchem 
BioAssay/Drug/Journal Article, 
Gene 
Bioassay/Drug/Article has found 
the gene term related the 
corresponding text; 
Bioassay/Drug/Article has a 
reference to the gene 
hasDisease 
Pubchem 
BioAssay/Drug/Journal Article, 
Disease 
Bioassay/Drug/Article has found 
the disease term related the 
corresponding text; 
 Bioassay/Drug/Article has a 
reference to the disease 
isAssociatedWith Gene, Disease Gene and disease is associated 
hasSimilarity Chemical Compound, Similarity Chemical has similarity value based on Tanimoto coefficient. 
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Table 2. CE triple examples based on CE Ontology 
CE Triple Examples 
WO:querycmpd WO:isSimilarTo  WO:cid24871487.  
WO:cid24871487 rdf:type WO:ChemicalCompound;  
                            WO:isActiveIn WO:aid1469.  
WO:aid1469 rdf:type WO:BioAssay;  
                     WO:hasGenes WO:COL4A4. 
WO:COL4A4 rdf:type WO:Gene;  
                       WO:isAssociatedWith WO:Nephritis. 
 
Figure 2 shows the network of possible relationships representing by above triples 
expressed in this system. Classes listed in Table 1 are shown in yellow ovals, like 
Journal Article, Chemical Compound, Gene, Disease, Bioassay, instances are in white 
ovals, black arrows show direct relationships mined from WENDI, and red arrows 
show inferred relationships mined from CE, like “Methysergide-Autistic_Disorder-
HTR1B”, “Methysergide-Lymphoma-CYP1A2” that can be derived from our rule 
base.  
Figure 2. RDF Network for CE 
 
Inference and the Rule Base  
Inference [26], in the context of SWT, is the discovery of new relationships from the 
known data modelled as a set of (named) relationships between resources and a set of 
rules automatically. In a mathematical sense, querying is a form of inference (being 
able to infer some search results from a mass of data, for example) [27]. We make 
inference to find new inferred relationships between compound and disease. 
Once the CE RDF triples are generated, they are loaded into Ont Model Class [28] in 
Jena [29], a Java Semantic Web Platform. We are performing the rule-based reasoner 
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and forward chaining over RDF graphs. A rule for the rule-based reasoner is defined 
by a Java Rule object with a list of body terms (premises), a list of head terms 
(conclusions) and an optional name and optional direction. Each term or ClauseEntry 
is either a triple pattern, an extended triple pattern or a call to a built-in primitive [29]. 
Total 8 rules have been defined in the CE system [30], 3 of them with explanations 
are listed below: 
[Rule 1: (?QueryCompound WO:isSimiliarTo ?CompoundID), 
 (?CompoundID WO:isActiveIn ?Bioassay), 
 (?Bioassay WO:isAssociatedWith ?Disease) 
-> (?QueryCompound WO:mightHasDisease ?Disease)] 
Explanation: A relationship is inferred between a compound and a disease if the query 
compound is similar to another compound that is active against a PubChem Bioassay, 
and that Bioassay is associated with a disease. 
[Rule 2: (?CompoundID WO:isContainedIn ?Journal), 
(?Journal WO:hasGene ?Gene), 
(?Gene WO:isAssociatedWith ?Disease) 
-> (?CompoundID WO:mightHasDisease ?Disease)] 
Explanation: A new compound-disease relationship is inferred if there a similar 
compound and a gene co-occur in a paper abstract, and the gene and disease co-occur 
in another paper abstract. 
[Rule 3: (?CompoundID WO:isActiveIn ?Bioassay), 
 (?Bioassay WO:hasGene ?Gene), 
 (?Gene WO:isAssociatedWith ?Disease) 
-> (?CompoundID WO:mightHasDisease ?Disease)] 
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Explanation: A new compound-disease relationship is inferred if a similar compound 
is active against a bioassay, the bioassay is associated with a gene, and the gene co-
occurs in a paper abstract with the disease. 
We selected Methysergide [31] as an example query compound for the following 
steps. Methysergide is chemically similar to LSD [32], and it antagonizes the effects 
of serotonin in blood vessels and gastrointestinal smooth muscle, but has few of the 
properties of other ergot alkaloids.  
Table 3 shows three RDF statements of Methysergide taken from CE RDF network. 
Based on that, we got inferred evidence paths by using above rules. Each statement 
along with explanation can be found in this Table 3. 
Table 3. CE RDF statement examples 
RDF Statements Explanation 
wo:ctdcid9681 rdf:type wo:ChemicalCompound.  
wo:querycmpd wo:isSimilarTo wo:ctdcid9681;  
                         wo:hasSimilarity "1.000".  
wo:ctdcid9681 wo:hasName "Methysergide".  
wo:HTR1B rdf:type wo:Gene; 
                   wo:isrelatedTo wo:cid9681;  
                   wo:isInferredFrom "pubmedid8743744". 
wo:Autistic_Disorder rdf:type wo:Disease;  
                                   wo:isAssociatedWith wo:HTR1B; 
                                   wo:isInferredFrom "pubmedid19038234". 
A Methysergide-
Autistic Disorder 
relationship is 
inferred via rule 2 
(gene HTR1B). 
The similar 
compound (cid = 
9681) is 
Methysergide itself 
with similarity = 1, 
it co-occurs with 
gene HTR1B in a 
same paper 
(pubmed id = 
8743744), and 
HTR1B and 
Autistic_Disorder 
are co-occurring in 
another same paper 
(pubmed id = 
19038234). Then 
we use rule 2 to 
establish such 
relations; 
 - 13 - 
wo:ctdcid11865408 rdf:type wo:ChemicalCompound.  
wo:querycmpd wo:isSimilarTo wo:ctdcid11865408;  
                         wo:hasSimilarity "0.774".  
wo:ctdcid11865408 wo:hasName "Metergoline".  
wo:HTR1B rdf:type wo:Gene; 
                   wo:isrelatedTo wo:cid11865408;  
                   wo:isInferredFrom "pubmedid1330643". 
wo:Autistic_Disorder rdf:type wo:Disease;  
                                   wo:isAssociatedWith wo:HTR1B; 
                                   wo:isInferredFrom "pubmedid19038234". 
A Methysergide-
Autistic Disorder 
relationship is also 
inferred via rule 2 
(again via 
HTR1B). Although 
this is the same 
relationship, a 
different evidence 
path considered 
(we will do path 
ranking on these 
evidence paths 
later); 
wo:cid5486180 rdf:type wo:ChemicalCompound.  
wo:querycmpd wo:isSimilarTo wo:cid5486180;  
                         wo:hasSimilarity "0.929".  
wo:cid5486180 wo:isActiveIn wo:aid410.  
wo:aid410 rdf:type wo:BioAssay;  
                 wo:hasName "p450-cyp1a2".  
wo:CYP1A2 rdf:type wo:Gene.  
wo:aid410 wo:hasGene wo:CYP1A2.  
wo:CYP1A2 wo:isAssociatedWith wo:Lymphoma.  
wo:Lymphoma rdf:type wo:Disease. 
A Methysergide-
Lymphoma 
relationship is 
inferred by rule1 
(via CYP1A2).  
 
Methysergide as the query compound, we got a total of 63 evidence paths with 
different diseases, genes, and journal information. Individual evidence paths can be 
examined to get to the root data or publications that constitute them. For instance, the 
Autism link is demonstrated is interesting as the publications identify the link of the 
compound with HTR1B and the link of HTR1B with Autism. LSD is known to affect 
the outcome of Autism [33, 34] and thus Methysergide is a reasonable candidate for 
investigation.  
Browsing RDF is clearly difficult, we have thus built an interface that allows the 
results to be examined and filtered in a user-friendly fashion, more details about the 
interface shows in the next section. Specifically, evidence paths are clustered by 
disease, and can be filtered via disease, compounds, assays, genes, gene families, or 
journal titles. Part of the results for Methysergide are shown in Figure 3, using 
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“Autistic_Disorder” as the filter, two similar compounds including Methysergide 
itself are related “Autistic_Disorder” with HTRB1 and a journal article. The results 
with AID “410” as the filter are shown in Figure 4. Total 20 entries associating with 
different similar compounds/diseases/genes/references are related the PubChem 
Bioassay (AID = 410). 
Figure 3. Results related to “Autistic_Disorder” for Methysergide shown in the 
CE Faced Browser by using Disease filter 
 
 
Figure 4. Results related to AID “410” for Methysergide shown in the CE Faced 
Browser by using AID filter  
 
Path Ranking  
The above process results in often many evidence paths linking compounds and 
diseases. With a large number of results, we need some way to organize and prioritize 
these evidence paths. We cluster all the paths based on the different disease terms and 
then rank the clusters based on the number of evidence paths linking them. Whilst 
evidence paths are not necessarily fully independent, they do constitute different 
collections of evidence for the same relationship, and thus strengthen the chances of 
the relationship being significant.  
We employ the following SPARQL query clause to implement this ranking process 
based on the inferred RDF. It counts the number of properties (?pc) related to each 
disease first, and then return disease terms (?dis) as descend order on the basis of  
(?pc). 
Select ?dis (count(?p) as ?pc)  
WHERE {?dis a wo:Disease;   ?p ?o} 
GROUP BY ?dis ORDER BY DESC(?pc) 
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Results and discussion  
The architecture for CE is shown in Figure 5. CE does data retrieval, data process, and 
data visualization. When query compound submitted to “Data Controller”, a servlet 
communicating with client and server, Data Controller sends the request to WENDI 
web service, after that, WENDI XML will be passed to “RDF Model Builder”, which 
handles: CE ontology generation, RDF converting, RDF inference, and path ranking. 
Ranked paths will be sent back to Data Controller to convert to RDF based JSON file 
for visualization by using the Faceted Browser. SPARQL query builder, is an 
additional CE user platform to make customized SPARQL queries based on CE RDF 
sent back from Data Controller.  
Figure 5. CE Architecture and Path Ranking Flowchart 
 
Faceted Browser for CE 
CE provides a main web interface, shown in Figure 6. In the Figure, Methysergide is 
drawn using the JME molecular editor, and its SMILES is transferred to the input box. 
And the results will be displayed in the Faceted Browser based on an existing tool[35] 
and allowing multiple filters to be applied.  
Figure 6. CE main Web Interface  
 
SPARQL Query Builder for CE 
After XML to RDF conversion, CE has RDF triples based on CE ontology. We 
therefore saw the utility of allowing the direct querying of this RDF data. Since 
SPARQL is a complex language, we implemented a SPARQL Query Builder to semi-
automate this process. The SPARQL query builder for CE is built based on the 
Sesame triple store [36]. The interface is shown in Figure 7. Starting with a class, the 
user can add data and object properties associated with it through prompted drop-
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down boxes. Step by step, the SPARQL query builder provides an intuitive way to 
translate user question into graph pattern, and then encode it into a SPARQL query. 
As an example, given the relationship of Methysergide [31] with HTR1B, LSD and 
Autism discussed, so we can explore the relationship of similar compounds with the 
serotonin 5-HT1B receptor (the LSD receptor) with a SPARQL query. We make the 
SPARQL query in the builder with the following 2 steps to get journal papers 
including information about “5-HT” receptor: 
1) Find similar compounds to Methysergide from the literatures, 
Subject: wo:ChemicalCompound 
Predict: wo:isContainedIn 
Object: wo:journalArticle 
2) The titles of the papers should include “5-HT”, 
Subject: wo: journalArticle 
Predict: wo:hasTitle 
Object: “5-HT” 
The implementation of this query is shown in Figure 7, and the list of journal titles 
including “5-HT” is shown in the result page of SPARQL Query Builder, in Table 4.  
Figure 7. Main Web Interface of CE SPARQL Query Builder 
 
Table 4. List of Journal Titles including “5-HT” receptor 
Journal Titles  
First Pharmacophoric Hypothesis for 5-HT7 Antagonism 
Novel, Potent, and Selective 5-HT3 Receptor Antagonists Based on the 
Arylpiperazine Skeleton: Synthesis, Structure, Biological Activity, and 
Comparative Molecular Field Analysis Studies 
Synthesis of 2-Piperazinylbenzothiazole and 2-Piperazinylbenzoxazole Derivatives 
with 5-HT3 Antagonist and 5-HT4 Agonist Properties 
Novel and Highly Potent 5-HT3 Receptor Agonists Based on a Pyrroloquinoxaline 
Structure 
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Identification of potential gene targets and diseases for Clozapine 
In order to validate CE, we tested it with well-known drugs as queries, to see how the 
ordering of the clusters of evidence paths related to known uses and side-effects for 
these drugs. For example Clozapine [37] has been shown to have superior efficacy 
when compared to olanzapine [38] in the treatment of schizophrenia [39]. Some 
known side effects of Clozapine, are cardiomyopathy (deterioration of the function of 
the myocardium), and cardiac hypertrophy. For this drug, CE indeed predominately 
returns compound-disease paths that relate to schizophrenia (i.e. schizophrenia has 
more evidence paths than any other disease). It also identifies side effects of the drug 
correctly as hypertrophic cardiomyopathy, and cardiovascular system disease, both of 
which are supported by the literature [40, 41]. This is shown in Figure 8.  
Figure 8. CE results for Clozapine 
 
Exploring newly submitted compounds from PubChem 
Pubchem is a popular public database of chemical compounds and their activities 
against biological assays. Since CE is designed for use with “new” compounds as 
queries (i.e. compounds for which there is not a lot of data available), we chose a set 
of very recently-added compounds in PubChem which had no or little associated 
bioactivity information recorded. This was done using a constrained search in 
PubChem [42] to return compounds submitted only in 2011.  
For example, as shown in Figure 9, the compound with CID 49835692 [43] has no 
associated bioactivity data recorded. However, through its analysis of similar 
structures, some significant potential bioactivities and disease associations are 
suggested by CE. 
Figure 9. More Chemogenomic information for New Compound from PubChem 
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We were using RDF network to make inference between compounds and diseases. As 
the experiments discussed before, not only the most related diseases could be sorted 
out, but also general guideline will be generated to conduct new compounds analysis. 
The power of the methodology has been clearly demonstrated to retrieve pertinent 
information in particular domain without any difficulties engendering by the data 
tsunami. In addition, it expands the possible usages/linkages within the limited 
volumes of disease information regarding to a specific compound. 
 
Conclusions  
We present a new approach to the association search of chemical compounds and 
diseases using semantic inference in this work. Semantic inference produces evidence 
paths relating compounds and diseases via genes, publication, bioassays and drugs.  
We previously released an aggregative data-mining tool, WENDI, for drug discovery 
using aggregate web services. In this paper, we have shown how the application of 
Semantic Web methods (RDF, SPARQL and OWL ontologies) along with rule-based 
inference, path ranking and a faceted browse, can produce a tool for exploring new 
compound-disease associations based on evidence paths from WENDI.   
 
Future work 
The current version of CE explores the chemogenomic information of chemical 
compounds. In the future, we will consider more efficient ways to mine compound-
gene, compound-disease links from more chemogenomic data, and plan to aggregate 
additional data and inference rules, also increase collaboration with Chem2Bio2RDF 
in order to enable CE to link with more diverse data. We also intend to expand 
beyond Chem2Bio2RDF to chemical biology, where we can consider other relations 
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like chemical-gene, chemical-pathway, chemical-side effect, etc. In addition, we 
would like to add the functionality to process batches of molecules. For this case, we 
will consider the issues of information summarization and visualization, i.e. how to 
organize more data in a readable way. Because of the increased volume of data and 
results, some current algorithms will become out of date. We will also take other 
ranking algorithms into account such as evidence importance. 
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